    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                                                                                                                                   	     <!DOCTYPE html><html><head><script id="f5_cspm">(function(){var f5_cspm={f5_p:'KEGKCAHHCPMNNJPOKIODBBJILHKGFKBJDFGNOCLLHNABEFFNFAPLNEBLMJNANOCACIFOJFDHOKIKKDJDAGMFEMBAIDHKAJPKIELDEPFGPJJFLGLIEHAAEEIOINCEOHMA',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}return;}}catch(err){return;}setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}f5_cspm.go();}());</script>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - FETZIMA- levomilnacipran hydrochloride capsule, extended release  FETZIMA- levomilnacipran hydrochloride    </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "FETZIMA- levomilnacipran hydrochloride capsule, extended release <br>FETZIMA- levomilnacipran hydrochloride   <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">FETZIMA- levomilnacipran hydrochloride capsule, extended release <br>FETZIMA- levomilnacipran hydrochloride   <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                                        <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFETZIMA%2D%20Levomilnacipran%20Hydrochloride%20Capsule%2C%20Extended%20Release%20FETZIMA%2D%20Levomi%2E%2E%2E%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Df371258d%2D91b3%2D4b6a%2Dac99%2D434a1964c3af%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=fet00-0002-04.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=fet00-0002-04.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" src="image.cfm?type=img&name=fet00-0002-04.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=fet00-0002-05.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=fet00-0002-05.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" src="image.cfm?type=img&name=fet00-0002-05.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                    <h4 class="more closed">VIEW MORE</h4>                                        <div class="show-more">                                            <ul>                                                                                                                        <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=fet00-0002-06.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="2">                                                <img id="zoom_3" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=fet00-0002-06.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" src="image.cfm?type=img&name=fet00-0002-06.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=fet00-0002-07.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="3">                                                <img id="zoom_4" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=fet00-0002-07.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" src="image.cfm?type=img&name=fet00-0002-07.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                                                                           <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=fet00-0002-08.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="4">                                                <img id="zoom_5" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=fet00-0002-08.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" src="image.cfm?type=img&name=fet00-0002-08.jpg&setid=f371258d-91b3-4b6a-ac99-434a1964c3af" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                            </ul>                                     </div>                                                                 </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22levomilnacipran%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=levomilnacipran" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=levomilnacipran" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=levomilnacipran[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=levomilnacipran/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=levomilnacipran/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=levomilnacipran/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=levomilnacipran[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=LEVOMILNACIPRAN+HYDROCHLORIDE+AND+levomilnacipran+hydrochloride&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0456-2202-28,                                                                                                                                        	                                    0456-2212-30,                                                                                                                                        	                                    0456-2212-90,                                                                                                                                        	                                    0456-2220-30,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    0456-2240-30,                                                                                                                                        	                                    0456-2240-90,                                                                                                                                        	                                    0456-2280-30,                                                                                                                                        	                                    0456-2280-90                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Forest Laboratories, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	07/14                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&amp;type=pdf&amp;name=f371258d-91b3-4b6a-ac99-434a1964c3af" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&amp;type=zip&amp;name=FETZIMA">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="s1"></a>  <a name="section-1"></a>   <p></p>   <h1>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS </h1>   <p class="First"> <span class="Bold">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older </span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s14">5.1</a>)]</span>. </p>   <p> <span class="Bold">In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber </span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s14">5.1</a>)]</span>. </p>   <p> <span class="Bold">FETZIMA is not approved for use in pediatric patients </span><span class="Bold Italics">[see Use in Specific Populations (<a href="#s47">8.4</a>)]</span>. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use FETZIMA safely and effectively. See full prescribing information for FETZIMA.    <br />FETZIMA   <span class="Sup">&reg;</span> (levomilnacipran) extended-release capsules, for oral use    <br />Initial U.S. Approval: 2009 (milnacipran)   </div>   <div class="Warning">    <div>     <h1 class="Warning"> <span class="Bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</span> </h1>     <h1 class="Warning"> <span class="Bold Italics">See full prescribing information for complete boxed warning.</span> </h1>     <ul class="Disc">      <li> <span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants (<a href="#s14">5.1</a>).</span> </li>      <li> <span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#s14">5.1</a>).</span> </li>      <li> <span class="Bold">FETZIMA is not approved for use in pediatric patients (<a href="#s47">8.4</a>).</span> </li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <table width="100%">      <colgroup>      <col width="75.000%" />       <col width="25.000%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left" colspan="2" valign="middle"> Contraindications - removed uncontrolled narrow-angle glaucoma (<a href="#s12">4</a>) </td>       </tr>       <tr>        <td align="right" colspan="2" valign="middle"> 07/2014 </td>       </tr>       <tr>        <td align="left" valign="middle"> Warnings and Precautions - Angle Closure Glaucoma (<a href="#s20">5.6</a>) </td>       <td align="right" valign="middle"> 07/2014 </td>       </tr>      </tbody>     </table>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) (<a href="#s2">1</a>). </p>     <p class="Highlighta"> <span class="Underline">Limitation of Use</span>: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established (<a href="#s2">1</a>). </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Italics">Recommended dose:</span> 40 mg to 120 mg once daily with or without food (<a href="#s4">2.1</a>). </li>      <li>Initiate dose at 20 mg once daily for 2 days and then increase to 40 mg once daily (<a href="#s4">2.1</a>). </li>      <li>Based on efficacy and tolerability, increase dose in increments of 40 mg at intervals of 2 or more days (<a href="#s4">2.1</a>). </li>      <li>The maximum recommended dose is 120 mg once daily (<a href="#s4">2.1</a>). </li>      <li>Take capsules whole; do not open, chew or crush (<a href="#s4">2.1</a>) </li>      <li> <span class="Italics">Renal Impairment:</span> Do not exceed 80 mg once daily for moderate impairment. Do not exceed 40 mg once daily for severe renal impairment (<a href="#s6">2.3</a>). </li>      <li> <span class="Italics">Discontinuation:</span> Reduce dose gradually whenever possible (<a href="#s7">2.4</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <ul class="Disc">      <li>Extended-release capsules: 20 mg, 40 mg, 80 mg and 120 mg (<a href="#s11">3</a>). </li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Italics">Hypersensitivity</span> to levomilnacipran, milnacipran HCl, or any excipient in the FETZIMA formulation (<a href="#s12">4</a>). </li>      <li> <span class="Italics">Serotonin Syndrome and MAOIs</span>: Do not use MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA. Do not use FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start FETZIMA in a patient who is being treated with linezolid or intravenous methylene blue (<a href="#s12">4</a>). </li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Italics">Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults</span>: Monitor patients for clinical worsening and suicidal thinking or behavior (<a href="#s14">5.1</a>). </li>      <li> <span class="Italics">Serotonin Syndrome</span>: Serotonin syndrome has been reported with SSRIs and SNRIs, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort). If such symptoms occur, discontinue FETZIMA and initiate supportive treatment. If concomitant use of FETZIMA with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases (<a href="#s16">5.2</a>). </li>      <li> <span class="Italics">Elevated Blood Pressure and Heart Rate</span>: Measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment. Control pre-existing hypertension before initiating therapy with FETZIMA (<a href="#s17">5.3</a>, <a href="#s18">5.4</a>). </li>      <li> <span class="Italics">Abnormal Bleeding</span>: Treatment can increase the risk of bleeding. Caution patients about the risk of bleeding associated with the use of NSAIDs, aspirin, or other drugs that affect coagulation (<a href="#s19">5.5</a>). </li>      <li> <span class="Italics">Angle Closure Glaucoma</span>: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants (<a href="#s20">5.6</a>). </li>      <li> <span class="Italics">Urinary Hesitation or Retention</span>: Can occur. If such symptoms occur, discontinue FETZIMA or consider other appropriate medical intervention (<a href="#s21">5.7</a>). </li>      <li> <span class="Italics">Activation of Mania/Hypomania</span>: Screen patients for bipolar disorder, Caution patients about risk of activation of mania/hypomania (<a href="#s22">5.8</a>). </li>      <li>Seizures: Can occur. Use with caution in patients with a seizure disorder (<a href="#s23">5.9</a>). </li>      <li> <span class="Italics">Discontinuation Syndrome</span>: Taper dose when possible and monitor for discontinuation symptoms (<a href="#s24">5.10</a>). </li>      <li> <span class="Italics">Hyponatremia</span>: Can occur in association with SIADH (<a href="#s25">5.11</a>). </li>     </ul>    </div>    <div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">The most common adverse reactions (incidence  5% and at least twice the rate of placebo) are: nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations (<a href="#s27">6.1</a>). </p>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Forest Pharmaceuticals, Inc. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Italics">Strong CYP3A4 inhibitors such as ketoconazole</span>: Do not exceed 80 mg once daily (<a href="#s33">7</a>). </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Italics">Pregnancy</span>: Based on animal data, may cause fetal harm (<a href="#s42">8.1</a>). </li>     </ul>    </div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>   </div>   <div></div>   <div>    <div></div>    <div>     <div></div>    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 7/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS </a> </h1>   <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a> </h1>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 General Instruction for Use </a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Maintenance/Continuation/Extended Treatment </a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Special Populations </a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Discontinuing Treatment </a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders </a> </h2>   <h2> <a href="#section-2.6" class="toc">2.6 Use of FETZIMA with Other MAOIs such as Linezolid or Methylene Blue </a> </h2>   <h2> <a href="#section-2.7" class="toc">2.7 Use of FETZIMA with Strong Inhibitors of Cytochrome P450 (CYP3A4) Enzyme </a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS </a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults </a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Serotonin Syndrome </a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Elevated Blood Pressure </a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Elevated Heart Rate </a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Abnormal Bleeding </a> </h2>   <h2> <a href="#section-5.6" class="toc"><span class="XmChange"></span>5.6 Angle Closure Glaucoma </a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Urinary Hesitation or Retention </a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Activation of Mania/Hypomania </a> </h2>   <h2> <a href="#section-5.9" class="toc">5.9 Seizures </a> </h2>   <h2> <a href="#section-5.10" class="toc">5.10 Discontinuation Syndrome </a> </h2>   <h2> <a href="#section-5.11" class="toc">5.11 Hyponatremia </a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS </a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Studies Experience </a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS </a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors (MAOIs) </a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Serotonergic Drugs </a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) </a> </h2>   <h2> <a href="#section-7.4" class="toc">7.4 Potential for Other Drugs to Affect FETZIMA </a> </h2>   <h2> <a href="#section-7.5" class="toc">7.5 Potential for FETZIMA to Affect Other Drugs </a> </h2>   <h2> <a href="#section-7.6" class="toc">7.6 Central Nervous System (CNS)-Active Agents </a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy </a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers </a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use </a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use </a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 Hepatic Impairment </a> </h2>   <h2> <a href="#section-8.6" class="toc">8.7 Renal Impairment </a> </h2>   <h2> <a href="#section-8.7" class="toc">8.8 Gender </a> </h2>   <h1> <a href="#section-9" class="toc">9 DRUG ABUSE AND DEPENDENCE </a> </h1>   <h2> <a href="#section-9.1" class="toc">9.1 Controlled Substance </a> </h2>   <h2> <a href="#section-9.2" class="toc">9.2 Abuse </a> </h2>   <h2> <a href="#section-9.3" class="toc">9.3 Dependence </a> </h2>   <h1> <a href="#section-10" class="toc">10 OVERDOSAGE </a> </h1>   <h2> <a href="#section-10.1" class="toc">10.1 Human Experience </a> </h2>   <h2> <a href="#section-10.2" class="toc">10.2 Management of Overdose </a> </h2>   <h1> <a href="#section-11" class="toc">11 DESCRIPTION </a> </h1>   <h1> <a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY </a> </h1>   <h2> <a href="#section-12.1" class="toc">12.1 Mechanism of Action </a> </h2>   <h2> <a href="#section-12.2" class="toc">12.2 Pharmacodynamics </a> </h2>   <h2> <a href="#section-12.3" class="toc">12.3 Pharmacokinetics </a> </h2>   <h1> <a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY </a> </h1>   <h2> <a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a> </h2>   <h1> <a href="#section-14" class="toc">14 CLINICAL STUDIES </a> </h1>   <h2> <a href="#section-14.1" class="toc">14.1 Treatment of Major Depressive Disorder </a> </h2>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a> </h1>   <h1> <a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION </a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="s2"></a>  <a name="section-1"></a>   <p></p>    <p class="First">FETZIMA, a serotonin and norepinephrine reuptake inhibitor (SNRI) is indicated for the treatment of major depressive disorder (MDD). The efficacy of FETZIMA was established in three 8-week, randomized, double-blind, placebo-controlled studies in adult patients with a diagnosis of MDD <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Clinical Studies (<a href="#s74">14</a>)]</span>. </p>   <p> <span class="Underline">Limitation of Use:</span> FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="s3"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s4"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 General Instruction for Use </h2>    <p class="First">The recommended dose range for FETZIMA is 40 mg to 120 mg once daily, with or without food.&nbsp; FETZIMA should be initiated at 20 mg once daily for 2 days and then increased to 40 mg once daily. Based on efficacy and tolerability, FETZIMA may then be increased in increments of 40 mg at intervals of 2 or more days.&nbsp;The maximum recommended dose is 120 mg once daily. </p>    <p>FETZIMA should be taken at approximately the same time each day. FETZIMA should be swallowed whole. Do not open, chew or crush the capsule. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s5"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Maintenance/Continuation/Extended Treatment </h2>    <p class="First">It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be reassessed periodically to determine the need for maintenance treatment and the appropriate dose for treatment. The efficacy of FETZIMA has not been established beyond 8 weeks. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s6"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Special Populations </h2>    <p class="First"> <span class="Italics">Renal Impairment</span>: Dose adjustment is not recommended in patients with mild renal impairment (creatinine clearance of 60-89 mL/min). For patients with moderate renal impairment (creatinine clearance of 30-59 mL/min), the maintenance dose should not exceed 80 mg once daily. For patients with severe renal impairment (creatinine clearance of 15-29 mL/min), the maintenance dose should not exceed 40 mg once daily. FETZIMA is not recommended for patients with end stage renal disease <span class="Italics">[see Use in Specific Populations (<a href="#s50">8.7</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s7"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Discontinuing Treatment </h2>    <p class="First">Discontinuation symptoms have been reported with discontinuation of serotonergic drugs such as FETZIMA. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients for these symptoms when discontinuing FETZIMA. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate <span class="Italics">[see Warnings and Precautions (<a href="#s24">5.10</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s8"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders </h2>    <p class="First">At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with FETZIMA. Conversely, at least 7 days should be allowed after stopping FETZIMA before starting an MAOI antidepressant <span class="Italics">[see Contraindications (<a href="#s12">4</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s9"></a>   <a name="section-2.6"></a>    <p></p>    <h2>2.6 Use of FETZIMA with Other MAOIs such as Linezolid or Methylene Blue </h2>    <p class="First">Do not start FETZIMA in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered <span class="Italics">[see Contraindications (<a href="#s12">4</a>)]</span>. </p>    <p>In some cases, a patient already receiving FETZIMA therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, FETZIMA should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with FETZIMA may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)]</span>. </p>    <p>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with FETZIMA is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s10"></a>   <a name="section-2.7"></a>    <p></p>    <h2>2.7 Use of FETZIMA with Strong Inhibitors of Cytochrome P450 (CYP3A4) Enzyme </h2>    <p class="First">The dose of FETZIMA should not exceed 80 mg once daily when used with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir) <span class="Italics">[see Drug Interactions (<a href="#s37">7.4</a>)]</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="s11"></a>  <a name="section-3"></a>   <p></p>    <p class="First">FETZIMA (levomilnacipran) is available as 20 mg, 40 mg, 80 mg and 120 mg extended-release capsules. </p>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col align="left" width="24.067%" />      <col align="left" width="32.433%" />      <col align="left" width="43.500%" />     </colgroup>    <tbody class="Headless">      <tr class="First">       <td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule<br />Strength</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule<br />Color/Shape</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule<br />Markings</span></td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" valign="middle">20 mg </td>      <td class="Botrule Rrule" align="center" valign="middle">yellow cap<br />white body </td>      <td class="Botrule Rrule" align="center" valign="middle">black &quot;FL&quot; on cap<br />black &quot;20&quot; on body </td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" valign="middle">40 mg </td>      <td class="Botrule Rrule" align="center" valign="middle">yellow cap<br />yellow body </td>      <td class="Botrule Rrule" align="center" valign="middle">black &quot;FL&quot; on cap<br />black &quot;40&quot; on body </td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" valign="middle">80 mg </td>      <td class="Botrule Rrule" align="center" valign="middle">pink cap<br />white body </td>      <td class="Botrule Rrule" align="center" valign="middle">black &quot;FL&quot; on cap<br />black &quot;80&quot; on body </td>      </tr>      <tr class="Last">       <td class="Botrule Lrule Rrule" align="center" valign="middle">120 mg </td>      <td class="Botrule Rrule" align="center" valign="middle">pink cap<br />pink body </td>      <td class="Botrule Rrule" align="center" valign="middle">black &quot;FL&quot; on cap<br />black &quot;120&quot; on body </td>      </tr>     </tbody>    </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="s12"></a>  <a name="section-4"></a>   <p></p>    <ul class="Disc">    <li style="border-left:1px solid;"> <span class="XmChange"></span>Hypersensitivity to levomilnacipran, milnacipran HCl or to any excipient in the formulation. </li>    <li style="border-left:1px solid;"> <span class="XmChange"></span>The use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. The use of FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated <span class="Italics">[see Dosage and Administration (<a href="#s8">2.5</a>) and Warnings and Precautions (<a href="#s16">5.2</a>)]</span>.<br />Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome <span class="Italics">[see Dosage and Administration (<a href="#s9">2.6</a>) and Warnings and Precautions (<a href="#s16">5.2</a>)]</span>. </li>   </ul>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="s13"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s14"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults </h2>    <p class="First">Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a longstanding concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phase of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. </p>    <p>The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <span class="Bold"><a href="#t1">Table 1</a></span>. </p>    <a name="t1"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 1 </span>      </caption>      <colgroup>      <col align="left" width="18.950%" />       <col align="left" width="81.050%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold Italics">Age Range</span></td>       <td class="Botrule Rrule Toprule" align="left" valign="middle">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Increases Compared to Placebo</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="middle">&lt;18 </td>       <td class="Botrule Rrule" align="center" valign="middle">14 additional cases </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="middle">18-24 </td>       <td class="Botrule Rrule" align="center" valign="middle">5 additional cases </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Decreases Compared to Placebo</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="middle">25-64 </td>       <td class="Botrule Rrule" align="center" valign="middle">1 fewer case </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="left" valign="middle">65 </td>       <td class="Botrule Rrule" align="center" valign="middle">6 fewer cases </td>       </tr>      </tbody>     </table>   </div>    <p>No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide. </p>    <p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression. </p>    <p> <span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span> </p>    <p>The following symptoms: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. </p>    <p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. </p>    <p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms <span class="Italics">[see Dosage and Administration (<a href="#s7">2.4</a>) and Warnings and Precautions (<a href="#s24">5.10</a>) for a description of the risks of discontinuation of FETZIMA]</span>. </p>    <p> <span class="Bold">Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers.</span> </p>    <p>Prescriptions for FETZIMA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s15"></a>    <a name="section-5.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Screening patients for bipolar disorder</span> </p>     <p>A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that FETZIMA is not approved for use in treating bipolar depression. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s16"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Serotonin Syndrome </h2>    <p class="First">The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). </p>    <p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome. </p>    <p>The concomitant use of FETZIMA with MAOIs intended to treat psychiatric disorders is contraindicated. FETZIMA should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking FETZIMA. FETZIMA should be discontinued before initiating treatment with the MAOI <span class="Italics">[</span><span class="Italics">see Dosage and Administration (<a href="#s8">2.5</a>, <a href="#s9">2.6</a>) </span><span class="Italics">and </span><span class="Italics">Contraindications (<a href="#s12">4</a>)]</span>. </p>    <p>If concomitant use of FETZIMA with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. </p>    <p>Treatment with FETZIMA and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s17"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Elevated Blood Pressure </h2>    <p class="First">SNRIs, including FETZIMA, have been associated with increases in blood pressure. Blood pressure should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing hypertension should be controlled before initiating treatment with FETZIMA. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. For patients who experience a sustained increase in blood pressure while receiving FETZIMA, discontinuation or other appropriate medical intervention should be considered. </p>    <p> <span class="Bold"><a href="#t2">Table 2</a></span> shows the mean changes in blood pressure, sustained hypertension, and upward shifts in hypertensive status that were observed in FETZIMA-treated patients in the short-term placebo-controlled studies. </p>    <a name="t2"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 2 Blood Pressure Mean Changes, Sustained Hypertension, and Upward Shifts in Hypertensive Status </span>      </caption>      <colgroup>      <col align="left" width="6.202%" />       <col align="left" width="66.917%" />       <col align="left" width="10.528%" />       <col align="left" width="16.354%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td align="left" colspan="4" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Normal Blood Pressure: SBP &lt; 120 mm Hg <span class="Bold Italics">and</span> DBP &lt; 80 mm Hg<br />Pre-hypertension: SBP  120 mm Hg <span class="Bold Italics">and</span>  139 mm Hg or DBP  80 mm Hg <span class="Bold Italics">and</span>  89 mm Hg<br />Stage I hypertension: SBP  140 mm Hg <span class="Bold Italics">and</span>  159 mm Hg or DBP  90 mm Hg <span class="Bold Italics">and</span>  99 mm Hg<br />Stage II hypertension: SBP  160 mm Hg <span class="Bold Italics">or</span> DBP  100 mm Hg </p> </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="middle"></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold Italics">Placebo</span> <br /> </td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold Italics">FETZIMA</span> <br /> <span class="Bold Italics">40-120 mg/day</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" colspan="4" valign="middle">Mean change from baseline to end of treatment, mm&nbsp;Hg </td>       </tr>       <tr>        <td class="Botrule Lrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="left" valign="middle">Systolic blood pressure (SBP) </td>       <td class="Botrule Rrule" align="center" valign="middle">-0.4 </td>       <td class="Botrule Rrule" align="center" valign="middle">3.0 </td>       </tr>       <tr>        <td class="Botrule Lrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="left" valign="middle">Diastolic blood pressure (DBP) </td>       <td class="Botrule Rrule" align="center" valign="middle">-0.0 </td>       <td class="Botrule Rrule" align="center" valign="middle">3.2 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" colspan="4" valign="middle">Sustained Hypertension, % of patients </td>       </tr>       <tr>        <td class="Botrule Lrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="left" valign="middle"><span class="Bold">Broad Criteria:</span> <br />SBP  140 mm Hg and an increase 15 mm Hg <span class="Bold Underline">OR</span> <br />DBP  90 mm Hg and an increase  10 mm Hg for at least 3 consecutive visits </td>       <td class="Botrule Rrule" align="center" valign="middle">1.2 </td>       <td class="Botrule Rrule" align="center" valign="middle">1.8 </td>       </tr>       <tr>        <td class="Botrule Lrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="left" valign="middle"><span class="Bold">Strict Criteria:</span> <br />SBP  140 mm Hg and an increase 15 mm Hg <span class="Bold Underline">AND</span> <br />DBP  90 mm Hg and an increase  10 mm Hg for at least 3 consecutive visits </td>       <td class="Botrule Rrule" align="center" valign="middle">0.1 </td>       <td class="Botrule Rrule" align="center" valign="middle">0.3 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" colspan="4" valign="middle">Upward Shifts in Hypertensive Status<span class="Sup">a</span>, % of patients </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule" align="left" valign="middle"></td>       <td class="Botrule Rrule" align="left" valign="middle">Normal/ Pre-hypertensive  Stage I/ Stage II </td>       <td class="Botrule Rrule" align="center" valign="middle">7.1 </td>       <td class="Botrule Rrule" align="center" valign="middle">10.4 </td>       </tr>      </tbody>     </table>   </div>    <p>In the short-term, placebo-controlled MDD studies, the mean increase from initiation of treatment in systolic BP was 3 mm Hg and diastolic BP was 3.2 mm Hg, as compared to no change in the placebo group. There were no dose-related changes in systolic and diastolic blood pressure observed. </p>    <p>In patients exposed to one-year, open-label treatment of FETZIMA (doses range from 40-120 mg once daily), the mean change from initiation of treatment in systolic BP was 3.9 mm Hg and diastolic BP was 3.1 mm Hg. </p>    <p>In the short-term, placebo-controlled studies, 11.6 % of patients met orthostatic hypotension criteria (SBP or DBP) in the FETZIMA group compared to 9.7% in the placebo group. Orthostatic reductions of blood pressure  10 mm Hg in DBP occurred in 5.8%, 6.1% and 9.8% of FETZIMA-treated patients with doses of 40, 80 and 120 mg/day respectively, compared to 6.2% of placebo-treated patients. </p>    <p>Concomitant use of FETZIMA with drugs that increase blood pressure and heart rate has not been evaluated and such combinations should be used with caution. Effects of FETZIMA on blood pressure in patients with significant hypertension or cardiac disease have not been systematically evaluated. FETZIMA should be used with caution in these patients. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s18"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Elevated Heart Rate </h2>    <p class="First">SNRIs including FETZIMA have been associated with increased heart rate. Heart rate should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing tachyarrhythmias and other cardiac disease should be treated before starting therapy with FETZIMA. For patients who experience a sustained increase in heart rate while receiving FETZIMA, discontinuation or other appropriate medical intervention should be considered. </p>    <p>In short-term clinical studies, FETZIMA treatment was associated with a mean increase in heart rate of 7.4 beats per minute (bpm) compared to a mean decrease of 0.3 bpm in placebo-treated patients. Heart rate increase in FETZIMA-treated patients receiving doses of 40&nbsp;mg, 80 mg and 120 mg was 7.2, 7.2, and 9.1 bpm. </p>    <p>FETZIMA has not been systematically evaluated in patients with a cardiac rhythm disorder. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s19"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Abnormal Bleeding </h2>    <p class="First">SSRIs and SNRIs, including FETZIMA, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. </p>    <p>Patients should be cautioned about the risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s20"></a>   <a name="section-5.6"></a>    <p></p>    <h2 style="border-left:1px solid;"> <span class="XmChange"></span>5.6 Angle Closure Glaucoma </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange"></span>The pupillary dilation that occurs following use of many antidepressant drugs including FETZIMA may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s21"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Urinary Hesitation or Retention </h2>    <p class="First">The noradrenergic effect of SNRIs including FETZIMA, can affect urethral resistance. In the controlled short-term studies, urinary hesitation occurred in 4%, 5% and 6% of FETZIMA-treated patients receiving doses of 40, 80 and 120 mg, respectively, compared to no patients in the placebo group. Caution is advised in the use of FETZIMA in patients prone to obstructive urinary disorders. If symptoms of urinary hesitation, urinary retention, or dysuria develop during treatment with FETZIMA, consideration should be given to the possibility that they might be drug-related, and discontinuation or other appropriate medical intervention should be considered. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s22"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Activation of Mania/Hypomania </h2>    <p class="First">Symptoms of mania/hypomania were reported in 0.2% of FETZIMA-treated patients and 0.2% of placebo-treated patients in clinical studies. Activation of mania/hypomania has also been reported in a small proportion of patients with mood disorders who were treated with other antidepressants. As with all antidepressants, use FETZIMA cautiously in patients with a history or family history of bipolar disorder, mania, or hypomania. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s23"></a>   <a name="section-5.9"></a>    <p></p>    <h2>5.9 Seizures </h2>    <p class="First">FETZIMA has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from clinical studies. FETZIMA should be prescribed with caution in patients with a seizure disorder. One case of seizure has been reported in pre-marketing clinical studies with FETZIMA. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s24"></a>   <a name="section-5.10"></a>    <p></p>    <h2>5.10 Discontinuation Syndrome </h2>    <p class="First">There have been reports of adverse events occurring upon discontinuation of serotonergic antidepressants, particularly when discontinuation is abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. </p>    <p>Monitor patients for these symptoms when discontinuing FETZIMA. Reduce the dose gradually whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, consider resuming the previously prescribed dose. Subsequently, the dose may be decreased, but at a more gradual rate <span class="Italics">[see Dosage and Administration (<a href="#s7">2.4</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s25"></a>   <a name="section-5.11"></a>    <p></p>    <h2>5.11 Hyponatremia </h2>    <p class="First">Although no adverse events of hyponatremia were reported for FETZIMA-treated patients in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. In many cases, hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. FETZIMA should be discontinued in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="s26"></a>  <a name="section-6"></a>   <p></p>    <p class="First">The following adverse reactions are discussed in greater detail in other sections of the label. </p>   <ul class="Disc">    <li>Hypersensitivity <span class="Italics">[see Contraindications (<a href="#s12">4</a>)]</span> </li>    <li>Suicidal Thoughts and Behaviors in Adolescents and Young Adults <span class="Italics">[see Warnings and Precautions (<a href="#s14">5.1</a>)]</span> </li>    <li>Serotonin Syndrome <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)]</span> </li>    <li>Elevated Blood Pressure <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)]</span> </li>    <li>Elevated Heart Rate <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.4</a>)]</span> </li>    <li>Abnormal Bleeding <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)]</span> </li>    <li>Angle Closure Glaucoma [<span class="Italics">see Warnings and Precautions (<a href="#s20">5.6</a>)]</span> </li>    <li>Urinary Hesitation or Retention <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>)]</span> </li>    <li>Activation of Mania/Hypomania <span class="Italics">[see Warnings and Precautions (<a href="#s22">5.8</a>)]</span> </li>    <li>Seizure [<span class="Italics">see Warnings and Precautions (<a href="#s23">5.9</a>)</span>] </li>    <li>Discontinuation Syndrome <span class="Italics">[see Warnings and Precautions (<a href="#s24">5.10</a>)]</span> </li>    <li>Hyponatremia <span class="Italics">[see Warnings and Precautions (<a href="#s25">5.11</a>)]</span> </li>   </ul>   <div class="Section" data-sectioncode="42229-5">    <a name="s27"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Studies Experience </h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s28"></a>    <a name="section-6.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Patient exposure</span> </p>     <p>The safety of FETZIMA was evaluated in 2,673 patients (18-78 years of age) diagnosed with MDD who participated in clinical studies, representing 942 patient-years of exposure. Among the 2,673 FETZIMA-treated patients, 1,583 were exposed to FETZIMA in short-term, placebo-controlled studies. There were 825 patients who continued from short-term studies into a one-year, open-label extension study. </p>     <p>Of the 2,673 patients exposed to at least one dose of FETZIMA, 737 patients were exposed to FETZIMA for at least 6 months and 367 were exposed for one year. In these studies FETZIMA was given at doses ranging from 40-120 mg once daily and was given without regard to food. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s29"></a>    <a name="section-6.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Adverse reactions reported as reasons for discontinuation of treatment</span> </p>     <p>In the short-term placebo-controlled pre-marketing studies for MDD, 9% of the 1,583 patients who received FETZIMA (40-120 mg) discontinued treatment due to an adverse event, compared with 3% of the 1,040 placebo-treated patients in those studies. The most common adverse reaction leading to discontinuation in at least 1% of the FETZIMA-treated patients in the short-term placebo-controlled studies was nausea (1.5%). </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s30"></a>    <a name="section-6.1.3"></a>     <p></p>     <p class="First"> <span class="Underline">Common adverse reactions in placebo-controlled MDD studies</span> </p>     <p>The most commonly observed adverse events in FETZIMA-treated MDD patients in placebo-controlled studies (incidence  5% and at least twice the rate of placebo) were: nausea, constipation, hyperhidrosis, heart rate increased, erectile dysfunction, tachycardia, vomiting, and palpitations. </p>     <p> <span class="Bold"><a href="#t3">Table 3</a></span> shows the incidence of adverse reactions that occurred in  2% of FETZIMA-treated MDD patients and at least twice the rate of placebo in the placebo-controlled studies. </p>     <a name="t3"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 3 Adverse Reactions Occurring in  2% of FETZIMA-treated Patients and at Least Twice the rate of Placebo-treated Patients </span>       </caption>       <colgroup>       <col align="left" width="41.267%" />        <col align="left" width="29.567%" />        <col align="left" width="29.167%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Tachycardia also includes: sinus tachycardia and postural orthostatic tachycardia syndrome </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">b</span> Percentage is relative to the number of patients in the associated demographic sex category. Fewer than 2% of FETZIMA-treated MDD female patients in placebo-controlled clinical studies reported adverse events related to sexual function. </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">c</span> erectile dysfunction includes: erectile dysfunction, organic erectile dysfunction and psychogenic erectile dysfunction </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">d</span> testicular pain includes: testicular pain, epididymitis, and seminal vesiculitis </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">e</span> ejaculation disorder includes: ejaculation disorder, ejaculation delayed, ejaculation failure, and premature ejaculation </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">f</span> Heart rate increased also includes: orthostatic heart rate response increased </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">g</span> Blood pressure increased also includes: blood pressure systolic increased, blood pressure diastolic increased and blood pressure orthostatic increased </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">h</span> Rash also includes: rash generalized, rash maculo-papular, rash erythematous and rash macular </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">i</span> Hypotension also includes: orthostatic hypotension and dizziness postural </p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">j</span> Hypertension also includes: labile hypertension </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="3" valign="top"> <p class="First Footnote">N = number of patients in the Safety Population </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold Italics">System Organ Class<br /> Preferred Term</span></td>        <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold Italics">Placebo</span> <br /> <span class="Bold Italics">(N =1040)</span> <br /> <span class="Bold Italics">%</span></td>        <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold Italics">FETZIMA <br />40-120 mg/d</span> <br /> <span class="Bold Italics">(N = 1583)<br />%</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Gastrointestinal disorders</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Nausea </td>        <td class="Botrule Rrule" align="center" valign="top">6 </td>        <td class="Botrule Rrule" align="center" valign="top">17 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Constipation </td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        <td class="Botrule Rrule" align="center" valign="top">9 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Vomiting </td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">5 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Cardiac disorders</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Tachycardia<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="top">2 </td>        <td class="Botrule Rrule" align="center" valign="top">6 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Palpitations </td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">5 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Reproductive system and breast disorders</span><span class="Bold"><span class="Sup">b</span></span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Erectile dysfunction<span class="Sup">c</span></td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">6 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Testicular pain<span class="Sup">d</span></td>        <td class="Botrule Rrule" align="center" valign="top">&lt;1 </td>        <td class="Botrule Rrule" align="center" valign="top">4 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Ejaculation disorder<span class="Sup">e</span></td>        <td class="Botrule Rrule" align="center" valign="top">&lt;1 </td>        <td class="Botrule Rrule" align="center" valign="top">5 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Investigations</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Heart rate increased<span class="Sup">f</span></td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">6 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Blood pressure increased<span class="Sup">g</span></td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="middle"><span class="Bold">Renal and urinary disorders</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Urinary hesitation </td>        <td class="Botrule Rrule" align="center" valign="top">0 </td>        <td class="Botrule Rrule" align="center" valign="top">4 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Hyperhidrosis </td>        <td class="Botrule Rrule" align="center" valign="top">2 </td>        <td class="Botrule Rrule" align="center" valign="top">9 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Rash<span class="Sup">h</span></td>        <td class="Botrule Rrule" align="center" valign="top">0 </td>        <td class="Botrule Rrule" align="center" valign="top">2 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Vascular disorders</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Hot flush </td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Hypotension<span class="Sup">i</span></td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Hypertension<span class="Sup">j</span></td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Metabolism and nutrition disorders</span></td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="top">Decreased appetite </td>        <td class="Botrule Rrule" align="center" valign="top">1 </td>        <td class="Botrule Rrule" align="center" valign="top">3 </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s31"></a>    <a name="section-6.1.4"></a>     <p></p>     <p class="First"> <span class="Underline">Dose-related adverse reactions</span> </p>     <p>In pooled data from the short-term placebo-controlled fixed-dose studies, there were no dose-related adverse reactions (greater than 2% overall incidence) in patients treated with FETZIMA across the dose range 40-120 mg once daily, with the exception of erectile dysfunction and urinary hesitation (see <span class="Bold"><a href="#t4">Table 4</a></span>). </p>     <a name="t4"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 4 Dose-Related Adverse Reactions </span>       </caption>       <colgroup>       <col align="left" width="34.420%" />        <col align="left" width="15.120%" />        <col align="left" width="18.000%" />        <col align="left" width="16.640%" />        <col align="left" width="15.820%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="5" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Percentage is relative to the number of male patients. </p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="5" valign="top"> <p class="First Footnote">N = number of patients in the Safety Population </p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle"><span class="Bold Italics">System Organ Class<br />&nbsp;Preferred Term</span></td>        <td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold Italics">Placebo<br />(N = 362)<br />%</span></td>        <td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold Italics">FETZIMA</span></td>        </tr>        <tr>         <td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">40 mg/d<br />(N = 366)<br />%</span></td>        <td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">80 mg/d<br />(N = 367)<br />%</span></td>        <td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">120 mg/d <br />(N = 180)<br />%</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="middle">Urinary hesitation </td>        <td class="Botrule Rrule" align="center" valign="middle">0 </td>        <td class="Botrule Rrule" align="center" valign="middle">4 </td>        <td class="Botrule Rrule" align="center" valign="middle">5 </td>        <td class="Botrule Rrule" align="center" valign="middle">6 </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="left" valign="middle">Erectile dysfunction<span class="Sup">a</span></td>        <td class="Botrule Rrule" align="center" valign="middle">2 </td>        <td class="Botrule Rrule" align="center" valign="middle">6 </td>        <td class="Botrule Rrule" align="center" valign="middle">8 </td>        <td class="Botrule Rrule" align="center" valign="middle">10 </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s32"></a>    <a name="section-6.1.5"></a>     <p></p>     <p class="First"> <span class="Underline">Other adverse reactions observed in clinical studies</span> </p>     <p>Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of &lt;&nbsp;2% in MDD patients treated with FETZIMA were: </p>     <p> <span class="Bold">Cardiac disorders:</span> Angina pectoris; Supraventricular and Ventricular extrasystoles </p>     <p> <span class="Bold">Eye disorders:</span> Dry eye; Vision blurred; Conjunctival hemorrhage </p>     <p> <span class="Bold">General disorders:</span> Chest pain; Thirst </p>     <p> <span class="Bold">Gastrointestinal disorders:</span> Abdominal pain; Flatulence </p>     <p> <span class="Bold">Investigations disorders:</span> Blood cholesterol increased; Liver function test abnormal </p>     <p> <span class="Bold">Nervous System disorders:</span> Migraine; Paraesthesia; Syncope; Extrapyramidal disorder </p>     <p> <span class="Bold">Psychiatric disorders:</span> Agitation; Anger; Bruxism; Panic attack; Tension; Aggression </p>     <p> <span class="Bold">Renal and Urinary disorder:</span> Pollakiuria; Hematuria; Proteinuria </p>     <p> <span class="Bold">Respiratory, thoracic and mediastinal disorders:</span> Yawning </p>     <p> <span class="Bold">Skin and subcutaneous tissue disorders:</span> Dry skin; Pruritus; Urticaria </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="s33"></a>  <a name="section-7"></a>   <p></p>    <p class="First">Other than CYP3A4 drug interactions, FETZIMA is predicted, based on <span class="Italics">in vitro</span> studies, to have a low potential to be involved in clinically significant pharmacokinetic drug interactions. </p>   <div class="Section" data-sectioncode="42229-5">    <a name="s34"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Monoamine Oxidase Inhibitors (MAOIs) </h2>    <p class="First"> <span class="Italics">[see Dosage and Administration (<a href="#s8">2.5</a>, <a href="#s9">2.6</a>), Contraindications (<a href="#s12">4</a>), and Warnings and Precautions (<a href="#s16">5.2</a>)]</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s35"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Serotonergic Drugs </h2>    <p class="First"> <span class="Italics">[see Dosage and Administration (<a href="#s8">2.5</a>, <a href="#s9">2.6</a>), Contraindications (<a href="#s12">4</a>), and Warnings and Precautions (<a href="#s16">5.2</a>)]</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s36"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) </h2>    <p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are co-administered with warfarin. Patients receiving warfarin therapy should be carefully monitored when FETZIMA is initiated or discontinued <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s37"></a>   <a name="section-7.4"></a>    <p></p>    <h2>7.4 Potential for Other Drugs to Affect FETZIMA </h2>    <p class="First">Dose adjustment is recommended when FETZIMA is co-administered with strong inhibitors of CYP3A4 (e.g. ketoconazole) <span class="Italics">[see Dosage and Administration (<a href="#s10">2.7</a>)].</span> An <span class="Italics">in vivo</span> study showed a clinically meaningful increase in levomilnacipran exposure when FETZIMA was co-administered with the CYP3A4 inhibitor ketoconazole (see <span class="Bold"><a href="#fig1">Figure 1</a></span>). </p>    <p>No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. <span class="Italics">In vivo</span> studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see <span class="Bold"><a href="#fig1">Figure 1</a></span>). </p>    <p>No dose adjustment of FETZIMA is needed when co-administered with inhibitors of CYP2C8 , CYP2C19, CYP2D6, CYP2J2, P-glycoprotein, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. <span class="Italics">In vitro</span> studies suggested that CYP2C8, CYP2C19, CYP2D6, and CYP2J2 had minimal contributions to metabolism of levomilnacipran. In addition, levomilnacipran is not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2 and is a weak substrate of P-gp.<br /> <br /> </p>    <p class="MultiMediaCaption"> <a name="fig1"></a><span class="Bold">Figure 1 PK Interactions between Levomilnacipran (LVM) and Other Drugs</span> </p>    <div class="Figure">     <a name="f01"></a>    <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D01%2Ejpg" alt="Figure 1" />   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s38"></a>   <a name="section-7.5"></a>    <p></p>    <h2>7.5 Potential for FETZIMA to Affect Other Drugs </h2>    <p class="First">No dose adjustment of the concomitant medication is recommended when FETZIMA is administered with a substrate of CYP3A4, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. <span class="Italics">In vitro</span> studies have shown that levomilnacipran is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. Concomitant use of FETZIMA with alprazolam or carbamazepine, substrates of CYP3A4, had no significant effect on alprazolam or carbamazepine plasma concentrations (see <span class="Bold"><a href="#fig1">Figure 1</a></span>). </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s39"></a>   <a name="section-7.6"></a>    <p></p>    <h2>7.6 Central Nervous System (CNS)-Active Agents </h2>    <p class="First">The risk of using FETZIMA in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised when FETZIMA is prescribed in combination with other CNS-active drugs, including those with a similar mechanism of action. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s40"></a>    <a name="section-7.6.1"></a>     <p></p>     <p class="First"> <span class="Underline">Alcohol</span> </p>     <p>In an <span class="Italics">in vitro</span> study, alcohol interacted with the extended-release properties of FETZIMA. If FETZIMA is taken with alcohol, a pronounced accelerated drug release may occur. It is recommended that FETZIMA extended-release capsules not be taken with alcohol. </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="s41"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="s42"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy </h2>    <p class="First">Pregnancy Category C </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s43"></a>    <a name="section-8.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Risk Summary</span> </p>     <p>There are no adequate and well-controlled studies of FETZIMA in pregnant women. Neonates exposed to dual reuptake inhibitors of serotonin and norepinephrine (such as FETZIMA), or selective serotonin reuptake inhibitors late in the third trimester have developed complications that can arise immediately upon delivery. Levomilnacipran was not teratogenic in rats or rabbits when given during the period of organogenesis at doses up to 8 or 16 times the maximum recommended human dose (MRHD) of 120 mg on a mg/m2 basis, respectively. However, an increase in early post natal rat pup mortality was seen at a dose equivalent to 5 times the MRHD given during pregnancy and lactation. FETZIMA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s44"></a>    <a name="section-8.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Clinical Considerations</span> </p>     <p>Neonates exposed to SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of these classes of drugs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)].</span> </p>     <p>A prospective longitudinal study of 201 women with history of major depression who were euthymic at the beginning of pregnancy, showed women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s45"></a>    <a name="section-8.1.3"></a>     <p></p>     <p class="First"> <span class="Underline">Animal Data</span> </p>     <p>No teratogenic effects were observed when levomilnacipran was administered to pregnant rats or rabbits during the period of organogenesis at oral doses up to 100 mg/kg/day. This dose is 8 and 16 times (in rats and rabbits, respectively) the maximum recommended human dose (MRHD) of 120 mg on a mg/m2 basis. Fetal body weights were reduced in rats, and skeletal ossification was delayed in both rats and rabbits at this dose; these effects were not observed in either species at doses up to 30 mg/kg/day, 2.4 times the MRHD in rats or 5 times the MRHD in rabbits. </p>     <p>When levomilnacipran was administered to pregnant rats at an oral dose of 60 mg/kg/day, 5 times the MRHD, during organogenesis and throughout pregnancy and lactation, there was an increase in early postnatal pup mortality; no pup mortality was seen at 20 mg/kg/day, 1.6 times the MRHD. Among the surviving pups, pre- and post-weaning pup weight gain was reduced up to at least 8 weeks of age; however, physical and functional development, including reproductive performance of the progeny, was not affected. The effects on body weight gain were not seen at 7 mg/kg/day, 0.6 times the MRHD. </p>    </div>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="s46"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers </h2>    <p class="First">It is not known if FETZIMA is present in human milk. Studies have shown that levomilnacipran is present in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from FETZIMA, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. </p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="s47"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use </h2>    <p class="First">Clinical studies on the use of FETZIMA in pediatric patients have not been conducted; therefore, the safety and effectiveness of FETZIMA in the pediatric population have not been established. FETZIMA is not approved for use in pediatric patients <span class="Italics">[see Boxed Warning and Warnings and Precautions (<a href="#s14">5.1</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="s48"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use </h2>    <p class="First">No dose adjustment is recommended on the basis of age (see <span class="Bold"><a href="#fig2">Figure 2</a></span>). In a multiple-dose clinical pharmacokinetic study, elderly subjects (&gt; 65 years) had a slightly higher exposure (C<span class="Sub">max</span> by 24% and AUC by 26%) of levomilnacipran than younger subjects (18-45 years). </p>    <p>Of the total number of subjects in clinical studies of FETZIMA, 2.8% of patients were age 65 or older. </p>    <p>Because levomilnacipran is predominately excreted by the kidney, renal clearance of levomilnacipran should be considered when determining the dose <span class="Italics">[see Dosage and Administration (<a href="#s6">2.3</a>)]</span>. </p>    <p>SSRIs and SNRIs, including FETZIMA, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event <span class="Italics">[see Warnings and Precautions (<a href="#s25">5.11</a>)].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s49"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 Hepatic Impairment </h2>    <p class="First">Hepatic elimination of levomilnacipran is low. Dose adjustment is not recommended in subjects with mild (Child-Pugh score of 1-6), moderate (Child-Pugh score of 7-9), or severe (Child-Pugh score of 10-13) hepatic impairment (see <span class="Bold"><a href="#fig2">Figure 2</a></span>). </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s50"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.7 Renal Impairment </h2>    <p class="First">Renal excretion plays a predominant role in the elimination of levomilnacipran. Dose adjustment is not recommended for patients with mild (creatinine clearance of 60-89 ml/min) renal impairment. Dosing adjustment is recommended for patients with moderate (creatinine clearance of 30-59 ml/min) or severe (creatinine clearance of 15-29 ml/min) renal impairment (see <span class="Bold"><a href="#fig2">Figure 2</a></span>). FETZIMA is not recommended for patients with end stage renal disease <span class="Italics">[see Dosage and Administration (<a href="#s6">2.3</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s51"></a>   <a name="section-8.7"></a>    <p></p>    <h2>8.8 Gender </h2>    <p class="First">Dose adjustment based on gender is not recommended (see <span class="Bold"><a href="#fig2">Figure 2</a></span>).<br /> <br /> </p>    <p class="MultiMediaCaption"> <a name="fig2"></a><span class="Bold">Figure 2 Effect of Intrinsic Factors on Levomilnacipran PK</span> </p>    <div class="Figure">     <a name="f02"></a>    <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D02%2Ejpg" alt="Figure 2" />   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a> <div class="Section toggle-content closed" data-sectioncode="42227-9">   <a name="s52"></a>  <a name="section-9"></a>   <p></p>    <div class="Section" data-sectioncode="34085-1">    <a name="s53"></a>   <a name="section-9.1"></a>    <p></p>    <h2>9.1 Controlled Substance </h2>    <p class="First">FETZIMA is not a controlled substance. </p>   </div>   <div class="Section" data-sectioncode="34086-9">    <a name="s54"></a>   <a name="section-9.2"></a>    <p></p>    <h2>9.2 Abuse </h2>    <p class="First">FETZIMA has not been systematically studied in animals or humans for its potential for abuse. There was no evidence suggestive of drug-seeking behavior in the clinical studies. It is not possible to predict on the basis of clinical experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of FETZIMA (e.g., development of tolerance or drug-seeking behavior). </p>   </div>   <div class="Section" data-sectioncode="34087-7">    <a name="s55"></a>   <a name="section-9.3"></a>    <p></p>    <h2>9.3 Dependence </h2>    <p class="First">FETZIMA has not been systematically studied in animals or humans for its potential for dependence. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="s56"></a>  <a name="section-10"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s57"></a>   <a name="section-10.1"></a>    <p></p>    <h2>10.1 Human Experience </h2>    <p class="First">There is limited clinical experience with FETZIMA overdose in humans. In clinical studies, cases of ingestions up to 360 mg daily were reported with none being fatal. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s58"></a>   <a name="section-10.2"></a>    <p></p>    <h2>10.2 Management of Overdose </h2>    <p class="First">No specific antidotes for FETZIMA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. In case of an overdose, consult a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice. The high volume of distribution of levomilnacipran suggests that dialysis will not be effective in reducing levomilnacipran plasma concentrations. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="s59"></a>  <a name="section-11"></a>   <p></p>    <p class="First">The active ingredient of FETZIMA is levomilnacipran, which is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). The chemical name of levomilnacipran is (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride; its empirical formula is C<span class="Sub">15</span>H<span class="Sub">23</span>ClN<span class="Sub">2</span>O and its molecular weight is 282.8 g/mol. Levomilnacipran (Initial US approval: 2013) is the 1S,2R-enantiomer of milnacipran. The chemical structure is: </p>   <div class="Figure">    <a name="f03"></a>   <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D03%2Ejpg" alt="Figure" />  </div>   <p>FETZIMA capsules are intended for oral administration only. Each FETZIMA capsule contains extended-release beads with 23.0, 45.9, 91.8, or 137.8 mg of levomilnacipran hydrochloride equivalent to 20, 40, 80, or 120 mg of levomilnacipran, respectively. Inactive ingredients include sugar spheres, ethylcellulose, talc, povidone, triethyl citrate, hypromellose, and titanium dioxide. Inactive ingredients also include shellac glaze, black iron oxide, yellow iron oxide (20 mg and 40 mg capsules only), and red iron oxide (80 mg and 120 mg capsules only). </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="s60"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="s61"></a>   <a name="section-12.1"></a>    <p></p>    <h2>12.1 Mechanism of Action </h2>    <p class="First">The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). </p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="s62"></a>   <a name="section-12.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics </h2>    <p class="First">Levomilnacipran binds with high affinity to the human serotonin (5-HT) and norepinephrine (NE) transporters (Ki = 11 and 91 nM, respectively) and potently inhibits 5-HT and NE reuptake (IC50 = 16-19 and 11 nM, respectively). Levomilnacipran lacks significant affinity for any other receptors, ion channels or transporters tested <span class="Italics">in vitro</span>, including serotonergic (5HT1-7), - and - adrenergic, muscarinic, or histaminergic receptors and Ca2+, Na+, K+ or Cl- channels. Levomilnacipran did not inhibit monoamine oxidase (MAO). </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s63"></a>    <a name="section-12.2.1"></a>     <p></p>     <p class="First"> <span class="Underline">Cardiovascular Electrophysiology</span> </p>     <p>At a dose 2.5 times the maximum recommended dose, levomilnacipran does not prolong QTc to any clinically relevant extent. </p>    </div>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="s64"></a>   <a name="section-12.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics </h2>    <p class="First">The concentration of levomilnacipran at steady state is proportional to dose when administered from 25 to 300 mg once daily. Following an oral administration, the mean apparent total clearance of levomilnacipran is 21-29 L/h. Steady-state concentrations of levomilnacipran are predictable from single-dose data. The apparent terminal elimination half-life of levomilnacipran is approximately 12 hours. After daily dosing of FETZIMA 120 mg, the mean C<span class="Sub">max</span> value is 341 ng/mL, and the mean steady-state AUC value is 5196 ng&middot;h/mL. Interconversion between levomilnacipran and its stereoisomer does not occur in humans. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="s65"></a>    <a name="section-12.3.1"></a>     <p></p>     <p class="First"> <span class="Underline">Absorption</span> </p>     <p>The relative bioavailability of levomilnacipran after administration of FETZIMA ER was 92% when compared to oral solution. Levomilnacipran concentration was not significantly affected when FETZIMA was administered with food. </p>     <p>The median time to peak concentration (Tmax) of levomilnacipran is 6-8 hours after oral administration. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s66"></a>    <a name="section-12.3.2"></a>     <p></p>     <p class="First"> <span class="Underline">Distribution</span> </p>     <p>Levomilnacipran is widely distributed with an apparent volume of distribution of 387-473 L; plasma protein binding is 22% over concentration range of 10 to 1000 ng/mL. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s67"></a>    <a name="section-12.3.3"></a>     <p></p>     <p class="First"> <span class="Underline">Metabolism</span> </p>     <p>Levomilnacipran undergoes desethylation to form desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran. Both oxidative metabolites undergo further conjugation with glucuronide to form conjugates. The desethylation is catalyzed primarily by CYP3A4 with minor contribution by CYP2C8, 2C19, 2D6, and 2J2 [<span class="Italics">see Drug Interactions (<a href="#s37">7.4</a>, <a href="#s38">7.5</a>)].</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s68"></a>    <a name="section-12.3.4"></a>     <p></p>     <p class="First"> <span class="Underline">Elimination/Excretion</span> </p>     <p>Levomilnacipran and its metabolites are eliminated primarily by renal excretion. Following oral administration of 14C-levomilnacipran solution, approximately 58% of the dose is excreted in urine as unchanged levomilnacipran. N-desethyl levomilnacipran is the major metabolite excreted in the urine and accounted for approximately 18% of the dose. Other identifiable metabolites excreted in the urine are levomilnacipran glucuronide (4%), desethyl levomilnacipran glucuronide (3%), p-hydroxy levomilnacipran glucuronide (1%), and p-hydroxy levomilnacipran (1%). The metabolites are inactive <span class="Italics">[see Dosage and Administration (<a href="#s6">2.3</a>)]</span>. </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="s69"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="s70"></a>   <a name="section-13.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s71"></a>    <a name="section-13.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Carcinogenesis</span> </p>     <p>Levomilnacipran administered by oral gavage to rats for 2 years and Tg.rasH2 mice for 6 months did not increase the incidence of tumors in either study. </p>     <p>Rats received levomilnacipran at doses up to 90/70 mg/kg/day (the dose was lowered in males after 45 weeks of dosing). The 90 mg/kg/day dose is 7 times the maximum recommended human dose (MRHD) of 120 mg on a mg/m2 basis. </p>     <p>Tg.rasH2 mice received levomilnacipran at doses up to 150 mg/kg/day. This dose is 6 times the MRHD. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s72"></a>    <a name="section-13.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Mutagenesis</span> </p>     <p>Levomilnacipran was not mutagenic in the <span class="Italics">in vitro</span> bacterial mutation assay (Ames test) and was not clastogenic in an <span class="Italics">in vivo</span> micronucleus assay in rats. Additionally, levomilnacipran was not genotoxic in the <span class="Italics">in vitro</span> mouse lymphoma (L5178Y TK+/-) cell forward mutation assay. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s73"></a>    <a name="section-13.1.3"></a>     <p></p>     <p class="First"> <span class="Underline">Impairment of Fertility</span> </p>     <p>When levomilnacipran was administered orally to male and female rats before mating, through mating and up to Day 7 of gestation at doses up to 100 mg/kg/day, no effects were observed on fertility. This dose is 8 times the MRHD. </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="s74"></a>  <a name="section-14"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s75"></a>   <a name="section-14.1"></a>    <p></p>    <h2>14.1 Treatment of Major Depressive Disorder </h2>    <p class="First">The efficacy of FETZIMA for the treatment of major depressive disorder (MDD) was established in three 8-week randomized, double-blind, placebo-controlled studies (at doses 40-120 mg once daily) in adult (18 - 78 years of age) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for MDD. Two of the studies were fixed dose (Study 1 and Study 2) and one study was flexible dose (Study&nbsp;3). </p>    <p>In Study 1, patients received 40 mg (n = 178), 80 mg (n = 179), or 120 mg (n = 180) of FETZIMA once daily, or placebo (n = 176).&nbsp; In Study 2, patients received either 40 mg (n = 188) or 80 mg (n = 188) of FETZIMA once daily, or placebo (n = 186).&nbsp; In the flexible-dose study (Study 3), patients received 40 to 120 mg (n = 217) of FETZIMA once daily, or placebo (n = 217) with 21%, 34%, and 44% of FETZIMA patients on 40 mg, 80 mg, and 120 mg, respectively at the end of their treatment. </p>    <p>In all three studies, FETZIMA demonstrated superiority over placebo in the improvement of depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score (see <span class="Bold"><a href="#t5">Table 5</a></span>). FETZIMA also demonstrated superiority over placebo as measured by improvement in the Sheehan Disability Scale (SDS) functional impairment total score. </p>    <a name="t5"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 5: Summary of Results for the Primary Efficacy Endpoint MADRS </span>      </caption>      <colgroup>      <col align="left" width="13.660%" />       <col align="left" width="28.820%" />       <col align="left" width="17.520%" />       <col align="left" width="20.000%" />       <col align="left" width="20.000%" />      </colgroup>     <tfoot>       <tr class="First">        <td align="left" colspan="5" valign="top"> <p class="First Footnote">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval unadjusted for multiplicity. </p> </td>       </tr>       <tr>        <td align="left" colspan="5" valign="top"> <p class="First Footnote"> <span class="Sup">a</span> Difference (drug minus placebo) in least-squares mean change from baseline to endpoint (Week 8). </p> </td>       </tr>       <tr class="Last">        <td align="left" colspan="5" valign="top"> <p class="First Footnote">* Doses statistically significantly superior to placebo. </p> </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Study Number</span></td>       <td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Treatment Group</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Mean Baseline Score (SD)</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">LS Mean Change from Baseline (SE)</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo-subtracted Difference</span><span class="Bold"><span class="Sup">a </span></span><span class="Bold">(95% CI)</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="top">Study 1<br />(fixed dose) </td>       <td class="Botrule Rrule" align="left" valign="middle">FETZIMA (ER 40 mg/day)* </td>       <td class="Botrule Rrule" align="center" valign="middle">36.0 (4.1) </td>       <td class="Botrule Rrule" align="center" valign="middle">-14.8 (1.0) </td>       <td class="Botrule Rrule" align="center" valign="middle">-3.2 (-5.9, -0.5) </td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="middle">FETZIMA (ER 80 mg/day)* </td>       <td class="Botrule Rrule" align="center" valign="middle">36.1 (3.9) </td>       <td class="Botrule Rrule" align="center" valign="middle">-15.6 (1.0) </td>       <td class="Botrule Rrule" align="center" valign="middle">-4.0 (-6.7, -1.3) </td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="middle">FETZIMA (ER 120 mg/day)* </td>       <td class="Botrule Rrule" align="center" valign="middle">36.0 (3.9) </td>       <td class="Botrule Rrule" align="center" valign="middle">-16.5 (1.0) </td>       <td class="Botrule Rrule" align="center" valign="middle">-4.9 (-7.6, -2.1) </td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="middle">Placebo </td>       <td class="Botrule Rrule" align="center" valign="middle">35.6 (4.5) </td>       <td class="Botrule Rrule" align="center" valign="middle">-11.6 (1.0) </td>       <td class="Botrule Rrule" align="center" valign="middle">-- </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top">Study 2<br />(fixed-dose) </td>       <td class="Botrule Rrule" align="left" valign="middle">FETZIMA (ER 40 mg/day)* </td>       <td class="Botrule Rrule" align="center" valign="middle">30.8 (3.4) </td>       <td class="Botrule Rrule" align="center" valign="middle">-14.6 (0.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-3.3 (-5.5, -1.1) </td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="middle">FETZIMA (ER 80 mg/day)* </td>       <td class="Botrule Rrule" align="center" valign="middle">31.2 (3.5) </td>       <td class="Botrule Rrule" align="center" valign="middle">-14.4 (0.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-3.1 (-5.3, -1.0) </td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="middle">Placebo </td>       <td class="Botrule Rrule" align="center" valign="middle">31.0 (3.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-11.3 (0.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-- </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Study 3 (flexible-dose) </td>       <td class="Botrule Rrule" align="left" valign="middle">FETZIMA (ER 40 - 120 mg/day)* </td>       <td class="Botrule Rrule" align="center" valign="middle">35.0 (3.6) </td>       <td class="Botrule Rrule" align="center" valign="middle">-15.3 (0.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-3.1 (-5.3, -0.9) </td>       </tr>       <tr class="Last">        <td class="Botrule Rrule" align="left" valign="middle">Placebo </td>       <td class="Botrule Rrule" align="center" valign="middle">35.2 (3.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-12.2 (0.8) </td>       <td class="Botrule Rrule" align="center" valign="middle">-- </td>       </tr>      </tbody>     </table>   </div>    <p>Post-hoc analyses of the relationships between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="s76"></a>  <a name="section-15"></a>   <p></p>    <p class="First">FETZIMA extended-release capsules are supplied in the following configurations: </p>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col align="left" width="12.162%" />      <col align="left" width="14.703%" />      <col align="left" width="18.684%" />      <col align="left" width="39.028%" />      <col align="left" width="15.423%" />     </colgroup>    <tbody class="Headless">      <tr class="First">       <td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule<br />Strength</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule<br />Color/Shape</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule<br />Markings</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Package<br />Configuration</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">NDC Code</span></td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle">20 mg </td>      <td class="Botrule Rrule" align="center" rowspan="2" valign="middle">yellow cap<br />white body </td>      <td class="Botrule Rrule" align="center" rowspan="2" valign="middle">black &quot;FL&quot; on cap<br />black &quot;20&quot; on body </td>      <td class="Botrule Rrule" align="center" valign="middle">Bottle / 30 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2220-30 </td>      </tr>      <tr>       <td class="Botrule Rrule" align="center" valign="middle">Hospital Unit Dose (Blister) / 10 x 10 </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2220-63 </td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle">40 mg </td>      <td class="Botrule Rrule" align="center" rowspan="3" valign="middle">yellow cap<br />yellow body </td>      <td class="Botrule Rrule" align="center" rowspan="3" valign="middle">black &quot;FL&quot; on cap<br />black &quot;40&quot; on body </td>      <td class="Botrule Rrule" align="center" valign="middle">Bottle / 30 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2240-30 </td>      </tr>      <tr>       <td class="Botrule Rrule" align="center" valign="middle">Bottle / 90 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2240-90 </td>      </tr>      <tr>       <td class="Botrule Rrule" align="center" valign="middle">Hospital Unit Dose (Blister) / 10 x 10 </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2240-63 </td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle">80 mg </td>      <td class="Botrule Rrule" align="center" rowspan="3" valign="middle">pink cap<br />white body </td>      <td class="Botrule Rrule" align="center" rowspan="3" valign="middle">black &quot;FL&quot; on cap<br />black &quot;80&quot; on body </td>      <td class="Botrule Rrule" align="center" valign="middle">Bottle / 30 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2280-30 </td>      </tr>      <tr>       <td class="Botrule Rrule" align="center" valign="middle">Bottle / 90 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2280-90 </td>      </tr>      <tr>       <td class="Botrule Rrule" align="center" valign="middle">Hospital Unit Dose (Blister) /10 x 10 </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2280-63 </td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle">120 mg </td>      <td class="Botrule Rrule" align="center" rowspan="3" valign="middle">pink cap<br />pink body </td>      <td class="Botrule Rrule" align="center" rowspan="3" valign="middle">black &quot;FL&quot; on cap<br />black &quot;120&quot; on body </td>      <td class="Botrule Rrule" align="center" valign="middle">Bottle / 30 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2212-30 </td>      </tr>      <tr>       <td class="Botrule Rrule" align="center" valign="middle">Bottle / 90 count </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2212-90 </td>      </tr>      <tr class="Last">       <td class="Botrule Rrule" align="center" valign="middle">Hospital Unit Dose (Blister) / 10 x 10 </td>      <td class="Botrule Rrule" align="center" valign="middle">0456-2212-63 </td>      </tr>     </tbody>    </table>  </div>   <p>FETZIMA Titration Pack is supplied in the following configuration: </p>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col align="left" width="15.983%" />      <col align="left" width="17.784%" />      <col align="left" width="23.725%" />      <col align="left" width="24.725%" />      <col align="left" width="17.784%" />     </colgroup>    <tbody class="Headless">      <tr class="First">       <td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule</span> <br /> <span class="Bold">Strength</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule</span> <br /> <span class="Bold">Color/Shape</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Capsule</span> <br /> <span class="Bold">Markings</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Package</span> <br /> <span class="Bold">Configuration</span></td>      <td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">NDC Code</span></td>      </tr>      <tr>       <td class="Botrule Lrule Rrule" align="center" valign="middle">20 mg </td>      <td class="Botrule Rrule" align="center" valign="middle">yellow cap<br />white body </td>      <td class="Botrule Rrule" align="center" valign="middle">black &quot;FL&quot; on cap<br />black &quot;20&quot; on body </td>      <td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Titration Pack (Blister) containing two 20 mg capsules and twenty-six 40 mg capsules<br /> </td>      <td class="Botrule Rrule" align="center" rowspan="2" valign="middle">0456-2202-28 </td>      </tr>      <tr class="Last">       <td class="Botrule Lrule Rrule" align="center" valign="middle">40 mg </td>      <td class="Botrule Rrule" align="center" valign="middle">yellow cap<br />yellow body </td>      <td class="Botrule Rrule" align="center" valign="middle">black &quot;FL&quot; on cap<br />black &quot;40&quot; on body </td>      </tr>     </tbody>    </table>  </div>   <div class="Section" data-sectioncode="44425-7">    <a name="s77"></a>   <a name="section-15.1"></a>    <p></p>    <p class="First"> <span class="Bold">Storage and Handling</span> </p>    <p>All package configurations: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F) <span class="Italics">[See USP Controlled Room Temperature]</span>. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="s78"></a>  <a name="section-16"></a>   <p></p>    <p class="First">See FDA-approved patient labeling (<a href="#s97">Medication Guide</a>) </p>   <div class="Section" data-sectioncode="42229-5">    <a name="s79"></a>   <a name="section-16.1"></a>    <p></p>    <p class="First"> <span class="Bold">Information for Patients</span> </p>    <p>Advise patients, their families, and their caregivers about the benefits and risks associated with treatment with FETZIMA and counsel them on its appropriate use. Advise patients, their families, and their caregivers to read the Medication Guide and assist them in understanding its contents. The complete text of the Medication Guide is reprinted at the end of this document. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s80"></a>   <a name="section-16.2"></a>    <p></p>    <p class="First"> <span class="Bold">Suicide Risk</span> </p>    <p>Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dose is adjusted up or down <span class="Italics">[see Box Warning and Warnings and Precautions (<a href="#s14">5.1</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s81"></a>   <a name="section-16.3"></a>    <p></p>    <p class="First"> <span class="Bold">Dosing and Administration</span> </p>    <p>Advise patients that FETZIMA should be swallowed whole and should not be chewed, crushed or opened. </p>    <p>Advise patients that FETZIMA can be taken with or without food. FETZIMA should be initiated with a dose of 20 mg once daily for 2 days and then increased to 40&nbsp;mg once daily. Based on efficacy and tolerability, FETZIMA may then be increased in increments of 40 mg at intervals of 2 or more days. The maximum recommended dose is 120 mg once daily. </p>    <p>Instruct patients if they miss a dose, to take the missed dose as soon as they remember. If it is almost time for the next dose, instruct them to skip the missed dose and take their next dose at the regular time. Advise them not to take two doses of FETZIMA at the same time. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s82"></a>   <a name="section-16.4"></a>    <p></p>    <p class="First"> <span class="Bold">Concomitant Medication</span> </p>    <p>Instruct patients not to take FETZIMA with an MAOI or within 14 days of stopping an MAOI and to allow 7 days after stopping FETZIMA before starting an MAOI <span class="Italics">[see Contraindications (<a href="#s12">4</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s83"></a>   <a name="section-16.5"></a>    <p></p>    <p class="First"> <span class="Bold">Serotonin Syndrome</span> </p>    <p>Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of FETZIMA and triptans, tramadol, tryptophan supplements, other serotonergic agents, or antipsychotic drugs <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>) and Drug Interactions (<a href="#s35">7.2</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s84"></a>   <a name="section-16.6"></a>    <p></p>    <p class="First"> <span class="Bold">Effect on Blood Pressure and Heart Rate</span> </p>    <p>Advise patients that they should have regular monitoring of blood pressure and heart rate when taking FETZIMA <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>, <a href="#s18">5.4</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s85"></a>   <a name="section-16.7"></a>    <p></p>    <p class="First"> <span class="Bold">Abnormal Bleeding</span> </p>    <p>Caution patients about the concomitant use of FETZIMA and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of abnormal bleeding <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s86"></a>   <a name="section-16.8"></a>    <p></p>    <p class="First"> <span class="Bold">Angle Closure Glaucoma</span> </p>    <p>Patients should be advised that taking FETZIMA can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when diagnosed, can be treated definitively with iridectomy. Open-angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.6</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s87"></a>   <a name="section-16.9"></a>    <p></p>    <p class="First"> <span class="Bold">Urinary Hesitation or Retention</span> </p>    <p>Caution patients about the risk of urinary hesitation and retention while taking FETZIMA, particularly in patients prone to obstructive urinary disorders <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s88"></a>   <a name="section-16.10"></a>    <p></p>    <p class="First"> <span class="Bold">Activation of Mania/Hypomania</span> </p>    <p>Advise patients and their caregivers to observe for signs of activation of mania/hypomania <span class="Italics">[see Warnings and Precautions (<a href="#s22">5.8</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s89"></a>   <a name="section-16.11"></a>    <p></p>    <p class="First"> <span class="Bold">Seizures</span> </p>    <p>Caution patients about using FETZIMA if they have a history of a seizure disorder <span class="Italics">[see Warnings and Precautions (<a href="#s23">5.9</a>)]</span>. Patients with a history of seizures were excluded from clinical studies. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s90"></a>   <a name="section-16.12"></a>    <p></p>    <p class="First"> <span class="Bold">Discontinuation Syndrome</span> </p>    <p>Advise patients not to stop taking FETZIMA without first talking with their healthcare provider. Patients should be aware that discontinuation effects may occur when suddenly stopping FETZIMA <span class="Italics">[see Warnings and Precautions (<a href="#s24">5.10</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s91"></a>   <a name="section-16.13"></a>    <p></p>    <p class="First"> <span class="Bold">Hyponatremia</span> </p>    <p>Advise patients that if they are treated with diuretics, or are otherwise volume depleted, or are elderly, they may be at greater risk of developing hyponatremia while taking FETZIMA <span class="Italics">[see Warnings and Precautions (<a href="#s25">5.11</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s92"></a>   <a name="section-16.14"></a>    <p></p>    <p class="First"> <span class="Bold">Alcohol</span> </p>    <p>Advise patients to avoid consumption of alcohol while taking FETZIMA <span class="Italics">[see Drug Interactions (<a href="#s39">7.6</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s93"></a>   <a name="section-16.15"></a>    <p></p>    <p class="First"> <span class="Bold">Allergic Reactions</span> </p>    <p>Advise patients to notify their healthcare provider if they develop an allergic reaction such as rash, hives, swelling, or difficulty breathing. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s94"></a>   <a name="section-16.16"></a>    <p></p>    <p class="First"> <span class="Bold">Pregnancy</span> </p>    <p>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during therapy with FETZIMA <span class="Italics">[see Use in Specific Populations (<a href="#s42">8.1</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s95"></a>   <a name="section-16.17"></a>    <p></p>    <p class="First"> <span class="Bold">Nursing Mothers</span> </p>    <p>Advise patients to notify their healthcare provider if they are breastfeeding an infant and would like to continue or start FETZIMA <span class="Italics">[see Use in Specific Populations (<a href="#s46">8.3</a>)]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s96"></a>   <a name="section-16.18"></a>    <p></p>    <p class="First"> <span class="Bold">Interference with Cognitive and Motor Performance</span> </p>    <p>Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that FETZIMA therapy does not adversely affect their ability to engage in such activities. </p>    <p>Licensed from Pierre Fabre Medicament </p>    <p>Distributed by:<br />Forest Pharmaceuticals, Inc.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, MO 63045 USA </p>    <p> <span class="Sup">&copy;</span> 2014 Forest Laboratories Inc. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="s97"></a>  <a name="section-17"></a>   <p></p>   <p class="First"> <span class="Bold">MEDICATION GUIDE</span> </p>   <p> <span class="Bold">FETZIMA<span class="Sup">&reg;</span> (fet-ZEE-muh)</span> </p>   <p> <span class="Bold">(levomilnacipran)</span> </p>   <p> <span class="Bold">extended-release capsules</span> </p>   <p>Read this Medication Guide before you start taking FETZIMA and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. </p>   <p> <span class="Bold">Talk to your healthcare provider about:</span> </p>   <ul class="Disc">    <li>all risks and benefits of treatment with antidepressant medicines </li>    <li>all treatment choices for depression or other serious mental illness </li>   </ul>   <p> <span class="Bold">What is the most important information I should know about depression, antidepressant medicines, other serious mental illnesses, suicidal thoughts or actions and serotonin syndrome?</span> </p>   <p>FETZIMA and other antidepressant medicines may cause serious side effects. </p>   <ol class="Arabic">    <li> <span class="Bold"> Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions.</span> These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness). </li>    <li> <span class="Bold"> Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. <br />FETZIMA is not approved for use in children.</span> Talk to your child's healthcare provider for more information. </li>    <li> <span class="Bold"> How can I watch for and try to prevent suicidal thoughts and actions?</span>     <ul class="Disc">      <li>Pay close attention to any changes in mood, behavior, thoughts, or feelings, especially sudden changes. This is very important when an antidepressant medicine is started or when the dose is changed. </li>      <li>Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. </li>      <li>Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. </li>     </ul> <p class="First"> <span class="Bold">Call your healthcare provider right away if you have any of the following symptoms or feelings, especially if they are new, worse, or worry you:</span> </p>     <ul class="Disc">      <li>attempts to commit suicide </li>      <li>acting on dangerous impulses </li>      <li>acting aggressive, being angry, or violent </li>      <li>thoughts about suicide or dying </li>      <li>new or worsening depression </li>      <li>new or worsening anxiety </li>      <li>feeling very agitated or restless </li>      <li>panic attacks </li>      <li>trouble sleeping </li>      <li>new or worsening irritability </li>      <li>an extreme increase in activity or talking (mania) </li>      <li>other unusual changes in behavior or mood </li>     </ul> </li>    <li> <span class="Bold"> Serotonin syndrome:</span> A rare, but potentially life-threatening condition called serotonin syndrome can happen when medicines such as FETZIMA are taken with certain other medicines. Serotonin syndrome can cause serious changes in how your brain, muscles, heart and blood vessels, and digestive system work. <br />Symptoms of serotonin syndrome may include:    <ul class="Disc">      <li>agitation, hallucinations, coma or other changes in mental status </li>      <li>problems controlling your movements or muscle twitching </li>      <li>fast heartbeat </li>      <li>high or low blood pressure </li>      <li>sweating or fever </li>      <li>nausea or vomiting </li>      <li>diarrhea </li>      <li>muscle stiffness or tightness </li>     </ul> </li>   </ol>   <p> <span class="Bold">What else do I need to know about antidepressant medicines?</span> </p>   <ul class="Disc">    <li> <span class="Bold">Antidepressants are medicines used to treat depression and other illnesses.</span> It is important to discuss all the risks of treating depression and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider, not just antidepressant medications. </li>    <li> <span class="Bold">Antidepressant medicines have other side effects.</span> Talk to your healthcare provider about the possible side effects of the medicine prescribed for you or your family member. </li>    <li> <span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you or your family member takes. Keep a list of all medicines (including prescription, over-the-counter, vitamins and herbal supplements) to show your healthcare provider. Do not start new medicines without first checking with your healthcare provider. </li>    <li> <span class="Bold">Never stop an antidepressant medicine without first talking to your healthcare provider.</span> Stopping an antidepressant medicine suddenly can cause other symptoms. </li>   </ul>   <p> <span class="Bold">What is FETZIMA?</span> </p>   <p>FETZIMA is a prescription medicine used to treat a certain type of depression called Major Depressive Disorder (MDD). FETZIMA belongs to a class of medicines known as SNRIs (or serotonin-norepinephrine reuptake inhibitors). </p>   <p> <span class="Bold">Who should not take FETZIMA?</span> </p>   <p> <span class="Bold">Do not take FETZIMA if you:</span> </p>   <ul class="Disc">    <li>are allergic to levomilnacipran, milnacipran HCl, or any of the ingredients in FETZIMA. See the end of this Medication Guide for a complete list of ingredients in FETZIMA. </li>    <li>take a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid or intravenous methylene blue. </li>    <li>have taken an MAOI within 14 days unless directed by your healthcare provider </li>    <li></li>   </ul>   <p> <a name="p01"></a><span class="Bold">What should I tell my healthcare provider before taking FETZIMA?</span> </p>   <p> <span class="Bold">Before you take FETZIMA, tell your healthcare provider if you</span>: </p>   <ul class="Disc">    <li>have high blood pressure </li>    <li>have heart problems </li>    <li>have or had bleeding problems </li>    <li>have or had urinary retention or problems urinating </li>    <li>have mania or bipolar disorder (manic depression) </li>    <li>have or had seizures or convulsions </li>    <li>have low salt (sodium) levels in your blood </li>    <li>have kidney problems </li>    <li>drink alcohol </li>    <li>are pregnant or plan to become pregnant. It is not known if FETZIMA will harm your unborn baby. </li>    <li>are breastfeeding or plan to breastfeed. It is not known if FETZIMA passes into breast milk. Talk to your healthcare provider if you are or plan to breast feed your baby while taking FETZIMA. </li>   </ul>   <p> <span class="Bold">Tell your healthcare provider about all the medicines that you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. </p>   <p> <span class="Bold">Especially tell your healthcare provider if you take:</span> </p>   <ul class="Disc">    <li>medicines used to treat migraine headache (triptans) </li>    <li>medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, fentanyl, tryptophan, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), buspirone, or antipsychotics </li>    <li>sibutramine </li>    <li>tramadol </li>    <li>over-the-counter supplements such as tryptophan or St. John's Wort </li>    <li>nonsteroidal anti-inflammatory drugs (NSAIDS) </li>    <li>aspirin </li>    <li>warfarin (Coumadin&reg;, Jantoven&reg;) </li>    <li>diuretics </li>   </ul>   <p>Ask your healthcare provider if you are not sure if you are taking any of these medicines. </p>   <p>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine. </p>   <p>FETZIMA and some medicines may affect each other, may not work as well, or may cause serious side effects when taken together. </p>   <p> <span class="Bold">How should I take FETZIMA?</span> </p>   <ul class="Disc">    <li>Take FETZIMA exactly as your healthcare provider tells you to take it. </li>    <li>Take FETZIMA at about the same time each day. </li>    <li>Your healthcare provider may need to change the dose of FETZIMA until it is the right dose for you. </li>    <li>Do not start or stop taking FETZIMA without talking to your healthcare provider first. Stopping FETZIMA suddenly can cause side effects. </li>    <li>FETZIMA may be taken with or without food. </li>    <li>Swallow FETZIMA whole. Do not chew, crush, or cut FETZIMA. </li>    <li>If you miss a dose of FETZIMA, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of FETZIMA at the same time. </li>    <li>If you take too much FETZIMA, call your healthcare provider or your poison control center at 1-800-222-1222, or go to the nearest hospital emergency room right away. </li>   </ul>   <p> <span class="Bold">What should I avoid while taking FETZIMA?</span> </p>   <ul class="Disc">    <li>FETZIMA can cause sleepiness or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how FETZIMA affects you. </li>    <li>You should not drink alcohol while taking FETZIMA. See <span class="Bold"><a href="#p01">What should I tell my healthcare provider before taking FETZIMA?</a></span> </li>   </ul>   <p> <span class="Bold">What are the possible side effects of FETZIMA?</span> </p>   <p> <span class="Bold">FETZIMA may cause serious side effects, including:</span> </p>   <ol class="Arabic">    <li> <span class="Bold"> high blood pressure</span> (hypertension). Your healthcare provider should evaluate your blood pressure before and while you are taking FETZIMA. If you have high blood pressure, it should be controlled before you start taking FETZIMA. </li>    <li> <span class="Bold"> increased heart rate (palpitations).</span> Your healthcare provider should evaluate your heart rate before and while you are taking FETZIMA. </li>    <li> <span class="Bold"> abnormal bleeding or bruising.</span> FETZIMA may increase your risk of bleeding or bruising, especially if you take the blood thinner warfarin (Coumadin&reg;, Jantoven&reg;), a non-steroidal anti-inflammatory drug (NSAID), or aspirin. </li>    <li> <span class="Bold">visual problems</span>     <ul class="Circle">      <li>eye pain </li>      <li>changes in vision </li>      <li>swelling or redness in or around eye<br /> </li>     </ul> Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are. </li>    <li> <span class="Bold"> urinary hesitation and retention</span> (difficulty urinating or unable to urinate) </li>    <li> <span class="Bold"> hypomania</span> (manic episodes). Symptoms of manic episodes include:    <ul class="Circle">      <li>greatly increased energy </li>      <li>severe problems sleeping </li>      <li>racing thoughts </li>      <li>reckless behavior </li>      <li>unusually grand ideas </li>      <li>excessive happiness or irritability </li>      <li>talking more or faster than usual </li>     </ul> </li>    <li> <span class="Bold"> seizures or convulsions</span> </li>    <li> <span class="Bold"> discontinuation symptoms:</span> Do not stop FETZIMA without first talking to your healthcare provider. Stopping FETZIMA suddenly may cause serious symptoms. including:    <ul class="Circle">      <li>anxiety </li>      <li>irritability </li>      <li>high or low mood </li>      <li>feeling restless or sleepy </li>      <li>headache </li>      <li>sweating </li>      <li>nausea </li>      <li>dizziness </li>      <li>electric shock-like sensations </li>      <li>tremor </li>      <li>confusion </li>     </ul> </li>    <li> <span class="Bold"> low levels of salt (sodium) in your blood</span>. Symptoms of this may include: headache, difficulty concentrating, memory changes, confusion, weakness and unsteadiness on your feet. Symptoms of severe or sudden cases of low salt levels in your blood may include: hallucinations (seeing or hearing things that are not real), fainting, seizures and coma. If not treated, severe low sodium levels could cause death. </li>   </ol>   <p>The most common side effects of FETZIMA include: </p>   <ul class="Disc">    <li>nausea or vomiting </li>    <li>constipation </li>    <li>sweating </li>    <li>erectile dysfunction </li>   </ul>   <p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>   <p>These are not all the possible side effects of FETZIMA. For more information, ask your healthcare provider or pharmacist. </p>   <p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>   <p> <span class="Bold">How should I store FETZIMA?</span> </p>   <p>Store FETZIMA at room temperature between 68&deg;F to 77&deg;F (20&deg;C to 25&deg;C). <span class="Bold">Keep FETZIMA and all medicines out of the reach of children.</span> </p>   <p> <span class="Bold">General information about the safe and effective use of FETZIMA.</span> </p>   <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FETZIMA for a condition for which it was not prescribed. Do not give FETZIMA to other people, even if they have the same condition. It may harm them. </p>   <p>This Medication Guide summarizes the most important information about FETZIMA. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about FETZIMA that is written for healthcare professionals. </p>   <p>For more information, go to www.FETZIMA.com or call 1-800-678-1605. </p>   <p> <span class="Bold">What are the ingredients in FETZIMA?</span> </p>   <p>Active ingredient: levomilnacipran hydrochloride </p>   <p>Inactive ingredients: sugar spheres, ethylcellulose, talc, povidone, triethyl citrate, hypromellose, titanium dioxide, shellac glaze, black iron oxide, yellow iron oxide (20 mg and 40 mg capsules only), red iron oxide (80 mg and 120 mg capsules only) </p>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration. </p>   <p>Licensed from Pierre Fabre Medicament </p>   <p>Distributed by:<br />Forest Pharmaceuticals, Inc.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, MO 63045 USA </p>   <p>Revised: July 2014 </p>   <p> <span class="Sup">&copy;</span> 2014 Forest Laboratories Inc. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s98"></a>  <a name="section-18"></a>   <p></p>   <p class="First">Principal Display panel  20 mg 30ct Bottle Label </p>   <p>Rx Only NDC 0456-2220-30 </p>   <p> <span class="Bold">Fetzima</span><span class="Sub"></span> <br />levomilnacipran<br />extended-release capsules </p>   <p>20 mg per capsule </p>   <p> <span class="Bold">Dispense the accompanying<br />Medication Guide to each patient.<br /> </span>30 capsules </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, Missouri 63045</span> </p>   <div class="Figure">    <a name="f04"></a>   <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D04%2Ejpg" alt="Principal Display panel  20 mg 30ct Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s99"></a>  <a name="section-19"></a>   <p></p>   <p class="First">Principal Display panel  40 mg 30ct Bottle Label </p>   <p>Rx Only NDC 0456-2240-30 </p>   <p> <span class="Bold">Fetzima</span><span class="Sub"></span> <br />levomilnacipran<br />extended-release capsules </p>   <p>40 mg per capsule </p>   <p> <span class="Bold">Dispense the accompanying<br />Medication Guide to each patient.<br /> </span>30 capsules </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, Missouri 63045</span> </p>   <div class="Figure">    <a name="f05"></a>   <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D05%2Ejpg" alt="Principal Display panel  40 mg 30ct Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s100"></a>  <a name="section-20"></a>   <p></p>   <p class="First">Principal Display panel  80 mg 30ct Bottle Label </p>   <p>Rx Only NDC 0456-2280-30 </p>   <p> <span class="Bold">Fetzima</span><span class="Sub"></span> <br />levomilnacipran<br />extended-release capsules </p>   <p>80 mg per capsule </p>   <p> <span class="Bold">Dispense the accompanying<br />Medication Guide to each patient.<br /> </span>30 capsules </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, Missouri 63045</span> </p>   <div class="Figure">    <a name="f06"></a>   <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D06%2Ejpg" alt="Principal Display panel  80 mg 30ct Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s101"></a>  <a name="section-21"></a>   <p></p>   <p class="First">Principal Display panel  120 mg 30ct Bottle Label </p>   <p>Rx Only NDC 0456-2212-30 </p>   <p> <span class="Bold">Fetzima</span><span class="Sub"></span> <br />levomilnacipran<br />extended-release capsules </p>   <p>120 mg per capsule </p>   <p> <span class="Bold">Dispense the accompanying<br />Medication Guide to each patient.<br /> </span>30 capsules </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, Missouri 63045</span> </p>   <div class="Figure">    <a name="f07"></a>   <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D07%2Ejpg" alt="Principal Display panel  120 mg 30ct Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s102"></a>  <a name="section-22"></a>   <p></p>   <p class="First">Principal Display Panel Titration Pack Label </p>   <p>Rx Only NDC 0456-2202-28 </p>   <p> <span class="Bold">Fetzima</span><span class="Sub"></span> <br />levomilnacipran<br />extended-release capsules </p>   <p> <span class="Bold">Titration Pack</span> </p>   <p>Two 20 mg Capsules<br /> <span class="Bold">Take one 20 mg capsule once daily<br />on Day 1 and Day 2.</span> </p>   <p>Twenty-six 40 mg Capsules<br /> <span class="Bold">Take one 40 mg capsule once daily<br />on Day 3 through Day 28.</span> </p>   <p> <span class="Bold">Patients: Lift up flap to find instructions for sliding out the tray.</span> </p>   <p> <span class="Bold">Dispense the accompanying Medication Guide to each patient.</span> </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, Missouri 63045</span> </p>   <div class="Figure">    <a name="f08"></a>   <img src="image.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af&name=fet00%2D0002%2D08%2Ejpg" alt="Principal Display Panel Titration Pack Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride capsule, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-2220</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>LEVOMILNACIPRAN HYDROCHLORIDE</strong> (UNII: 371U2ZK31U) (levomilnacipran - UNII:UGM0326TXX)</td>          <td class="formItem">levomilnacipran</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SUCROSE</strong> (UNII: C151H8M554)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ethylcelluloses</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triethyl citrate</strong> (UNII: 8Z96QXD6UM)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>shellac</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">yellow (Yellow) ,&nbsp;white (White)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE (CAPSULE)</td>          <td class="formLabel">Size</td>          <td class="formItem">14mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FL;20</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-2220-30</td>          <td class="formItem">30 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem">07/25/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride capsule, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-2240</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>LEVOMILNACIPRAN HYDROCHLORIDE</strong> (UNII: 371U2ZK31U) (levomilnacipran - UNII:UGM0326TXX)</td>          <td class="formItem">levomilnacipran</td>          <td class="formItem">40&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SUCROSE</strong> (UNII: C151H8M554)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ethylcelluloses</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triethyl citrate</strong> (UNII: 8Z96QXD6UM)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>shellac</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">yellow (Yellow)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE (CAPSULE)</td>          <td class="formLabel">Size</td>          <td class="formItem">16mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FL;40</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-2240-30</td>          <td class="formItem">30 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-2240-90</td>          <td class="formItem">90 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem">07/25/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride capsule, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-2280</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>LEVOMILNACIPRAN HYDROCHLORIDE</strong> (UNII: 371U2ZK31U) (levomilnacipran - UNII:UGM0326TXX)</td>          <td class="formItem">levomilnacipran</td>          <td class="formItem">80&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SUCROSE</strong> (UNII: C151H8M554)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ethylcelluloses</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triethyl citrate</strong> (UNII: 8Z96QXD6UM)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>shellac</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">pink (Pink) ,&nbsp;white (White)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE (CAPSULE)</td>          <td class="formLabel">Size</td>          <td class="formItem">18mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FL;80</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-2280-30</td>          <td class="formItem">30 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-2280-90</td>          <td class="formItem">90 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem">07/25/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride capsule, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-2212</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>LEVOMILNACIPRAN HYDROCHLORIDE</strong> (UNII: 371U2ZK31U) (levomilnacipran - UNII:UGM0326TXX)</td>          <td class="formItem">levomilnacipran</td>          <td class="formItem">120&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SUCROSE</strong> (UNII: C151H8M554)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ethylcelluloses</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triethyl citrate</strong> (UNII: 8Z96QXD6UM)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>shellac</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">pink (Pink)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE (CAPSULE)</td>          <td class="formLabel">Size</td>          <td class="formItem">19mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FL;120</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-2212-30</td>          <td class="formItem">30 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-2212-90</td>          <td class="formItem">90 in 1 BOTTLE, PLASTIC</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem">07/25/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride kit</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-2202</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-2202-28</td>          <td class="formItem">1 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Quantity of Parts</td>          </tr>          <tr>           <th class="formTitle" width="5" scope="col">Part&nbsp;#</th>          <th class="formTitle" scope="col">Package Quantity</th>          <th class="formTitle" scope="col">Total Product Quantity</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem" width="5"><strong>Part 1</strong></td>          <td class="formItem"></td>          <td class="formItem">2&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem" width="5"><strong>Part 2</strong></td>          <td class="formItem"></td>          <td class="formItem">26&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 1 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride capsule, extended release</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>levomilnacipran hydrochloride</strong> (UNII: 371U2ZK31U) (levomilnacipran - UNII:UGM0326TXX)</td>          <td class="formItem">levomilnacipran</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SUCROSE</strong> (UNII: C151H8M554)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ethylcelluloses</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triethyl citrate</strong> (UNII: 8Z96QXD6UM)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>shellac</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">yellow (yellow) ,&nbsp;white (white)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE (CAPSULE)</td>          <td class="formLabel">Size</td>          <td class="formItem">14mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FL;20</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem">07/25/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 2 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>FETZIMA&nbsp; </strong> <br /> <span class="contentTableReg">levomilnacipran hydrochloride capsule, extended release</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>levomilnacipran hydrochloride</strong> (UNII: 371U2ZK31U) (levomilnacipran - UNII:UGM0326TXX)</td>          <td class="formItem">levomilnacipran</td>          <td class="formItem">40&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SUCROSE</strong> (UNII: C151H8M554)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ethylcelluloses</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triethyl citrate</strong> (UNII: 8Z96QXD6UM)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>shellac</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">yellow (yellow)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE (CAPSULE)</td>          <td class="formLabel">Size</td>          <td class="formItem">16mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FL;40</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA204168</td>          <td class="formItem">07/25/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Forest Laboratories, Inc. (001288281) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Forest Pharmaceuticals Inc</td>      <td class="formItem"></td>      <td class="formItem">139645477</td>      <td class="formItem">PACK(0456-2220, 0456-2240, 0456-2280, 0456-2212, 0456-2202)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Pierre Fabre Medicament -Plantes &amp; Industrie</td>      <td class="formItem"></td>      <td class="formItem">267116254</td>      <td class="formItem">API MANUFACTURE(0456-2220, 0456-2240, 0456-2280, 0456-2212, 0456-2202)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22levomilnacipran%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=levomilnacipran" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=levomilnacipran" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=LEVOMILNACIPRAN+HYDROCHLORIDE+AND+levomilnacipran+hydrochloride&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">FETZIMA- levomilnacipran hydrochloride capsule, extended release <br>FETZIMA- levomilnacipran hydrochloride   <br></h3>            <h4>Number of versions: 3</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jul 29, 2014</td>                        <td>							                                5                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=146594">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 1, 2013</td>                        <td>							                                4                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=123161">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 16, 2013</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=117122">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">FETZIMA- levomilnacipran hydrochloride capsule, extended release <br>FETZIMA- levomilnacipran hydrochloride   <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433217">1433217</a></td>                              <td>levomilnacipran 120 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433217">1433217</a></td>                              <td>24 HR levomilnacipran 120 MG Extended Release Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433217">1433217</a></td>                              <td>levomilnacipran 120 MG (as levomilnacipran hydrochloride 137.8 MG) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433223">1433223</a></td>                              <td>Fetzima 120 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433223">1433223</a></td>                              <td>24 HR levomilnacipran 120 MG Extended Release Oral Capsule [Fetzima]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433223">1433223</a></td>                              <td>24 HR Fetzima 120 MG Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433223">1433223</a></td>                              <td>Fetzima (levomilnacipran 120 MG (as levomilnacipran hydrochloride 137.8 MG)) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433223">1433223</a></td>                              <td>Fetzima 120 MG 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433227">1433227</a></td>                              <td>levomilnacipran 20 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433227">1433227</a></td>                              <td>24 HR levomilnacipran 20 MG Extended Release Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433227">1433227</a></td>                              <td>levomilnacipran 20 MG (as levomilnacipran hydrochloride 23 MG) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433229">1433229</a></td>                              <td>Fetzima 20 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433229">1433229</a></td>                              <td>24 HR levomilnacipran 20 MG Extended Release Oral Capsule [Fetzima]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>14</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433229">1433229</a></td>                              <td>24 HR Fetzima 20 MG Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>15</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433229">1433229</a></td>                              <td>Fetzima (levomilnacipran 20 MG (as levomilnacipran hydrochloride 23 MG)) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>16</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433229">1433229</a></td>                              <td>Fetzima 20 MG 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>17</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433233">1433233</a></td>                              <td>levomilnacipran 40 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>18</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433233">1433233</a></td>                              <td>24 HR levomilnacipran 40 MG Extended Release Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>19</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433233">1433233</a></td>                              <td>levomilnacipran 40 MG (as levomilnacipran hydrochloride 45.9 MG) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>20</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433233">1433233</a></td>                              <td>levomilnacipran 40 MG 24HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>21</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433235">1433235</a></td>                              <td>Fetzima 40 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>22</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433235">1433235</a></td>                              <td>24 HR levomilnacipran 40 MG Extended Release Oral Capsule [Fetzima]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>23</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433235">1433235</a></td>                              <td>24 HR Fetzima 40 MG Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>24</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433235">1433235</a></td>                              <td>Fetzima (levomilnacipran 40 MG (as levomilnacipran hydrochloride 45.9 MG)) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>25</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433235">1433235</a></td>                              <td>Fetzima 40 MG 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>26</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433239">1433239</a></td>                              <td>levomilnacipran 80 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>27</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433239">1433239</a></td>                              <td>24 HR levomilnacipran 80 MG Extended Release Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>28</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433239">1433239</a></td>                              <td>levomilnacipran 80 MG (as levomilnacipran hydrochloride 91.8 MG) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>29</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433239">1433239</a></td>                              <td>levomilnacipran 80 MG 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>30</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433241">1433241</a></td>                              <td>Fetzima 80 MG 24HR Extended Release Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>31</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433241">1433241</a></td>                              <td>24 HR levomilnacipran 80 MG Extended Release Oral Capsule [Fetzima]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>32</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433241">1433241</a></td>                              <td>24 HR Fetzima 80 MG Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>33</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433241">1433241</a></td>                              <td>Fetzima (levomilnacipran 80 MG (as levomilnacipran hydrochloride 91.8 MG)) 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>34</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433241">1433241</a></td>                              <td>Fetzima 80 MG 24 HR Extended Release Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>35</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433249">1433249</a></td>                              <td>{2 (24 HR levomilnacipran 20 MG Extended Release Oral Capsule) / 26 (24 HR levomilnacipran 40 MG Extended Release Oral Capsule) } Pack</td>                        <td>GPCK</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>36</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433250">1433250</a></td>                              <td>Fetzima Titration Pack, 20 MG (2), 40 MG (26)</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>37</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433250">1433250</a></td>                              <td>{2 (24 HR levomilnacipran 20 MG Extended Release Oral Capsule [Fetzima]) / 26 (24 HR levomilnacipran 40 MG Extended Release Oral Capsule [Fetzima]) } Pack [Fetzima Pack]</td>                        <td>BPCK</td>                    </tr>                   	                                                    <tr>                                                                    <td>38</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1433250">1433250</a></td>                              <td>Fetzima Titration Pack</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">FETZIMA- levomilnacipran hydrochloride capsule, extended release <br>FETZIMA- levomilnacipran hydrochloride   <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                                        <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFETZIMA%2D%20Levomilnacipran%20Hydrochloride%20Capsule%2C%20Extended%20Release%20FETZIMA%2D%20Levomi%2E%2E%2E%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Df371258d%2D91b3%2D4b6a%2Dac99%2D434a1964c3af%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    